Abstract. The purpose of this study was to investigate the potential therapeutic qualities of 9 -tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer's disease. N2a-variant amyloid-␤ protein precursor (A␤PP) cells were incubated with THC and assayed for amyloid-␤ (A␤) levels at the 6-, 24-, and 48-hour time marks. THC was also tested for synergy with caffeine, in respect to the reduction of the A␤ level in N2a/A␤PPswe cells. THC was also tested to determine if multiple treatments were beneficial. The MTT assay was performed to test the toxicity of THC. Thioflavin T assays and western blots were performed to test the direct anti-A␤ aggregation significance of THC. Lastly, THC was tested to determine its effects on glycogen synthase kinase-3␤ (GSK-3␤) and related signaling pathways. From the results, we have discovered THC to be effective at lowering A␤ levels in N2a/A␤PPswe cells at extremely low concentrations in a dose-dependent manner. However, no additive effect was found by combining caffeine and THC together. We did discover that THC directly interacts with A␤ peptide, thereby inhibiting aggregation. Furthermore, THC was effective at lowering both total GSK-3␤ levels and phosphorylated GSK-3␤ in a dose-dependent manner at low concentrations. At the treatment concentrations, no toxicity was observed and the CB1 receptor was not significantly upregulated. Additionally, low doses of THC can enhance mitochondria function and does not inhibit melatonin's enhancement of mitochondria function. These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer's disease through multiple functions and pathways.
INTRODUCTION
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In 2011 alone, 15 million family members have pro-27 vided more than 17.4 billion hours of care to diagnosed 28 Alzheimer's disease (AD) patients. That care translates 29 into more than $210 billion of AD-related services [1] .
that A␤ (A␤ 40 ) and A␤ (A␤ 42 
56
Recent studies have also suggested that glycogen 57 synthase kinase 3 (GSK-3) has a key role in the patho-58 genesis of both sporadic and familial AD [11, 12] . It 59 has been reported that GSK-3␤ induces hyperphos-60 phorylation of tau [13] [14] [15] [16] [17] . Moreover, overexpression resulting in A␤-mediated neuronal death [18] . Addi- and neurofibrillary tangle formation [19] . Some reports 71 have also indicated that GSK-3␣ plays a role in regu-72 lating amyloid-␤ protein precursor (A␤PPP) cleavage, 73 resulting in increased A␤ production [20, 21] . It has 74 also been shown that the A␤ load in mouse brain can 75 be robustly ameliorated by the inhibition of GSK-3␤ 76 [22] . interrupted early in the course of AD [24] . To the con-92 trary, CB 2 receptor expression is more limited and has 93 been anatomically found in neurons within the brain-94 stem [25] , cerebellum [26] , and microglia [27] 100 U/mL penicillin, 100 g/mL streptomycin, and 187 400 g/mL G418 (Invitrogen), at 37 • C in the pres- HRP sigma A9044. 1:5000 diluted in blocking buffer).
254
After membrane was developed, film with bands were showed a significant decrease in A␤ 40 concentra-341 tion compared to cells treated once (Fig. 3A) . While to the cells at each concentration assayed (Fig. 3B) . the mitochondria is not altered (Fig. 9A, B) .
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DISCUSSION
428
Advances in therapeutics to prevent AD, or delay the are thought to be central to the pathogenesis of AD [41] .
434
Similarly, the current study shows the in vitro anti-A␤ Graph representing the expression decrease in GSK-3␤ in a dose-dependent manner by using ␤-actin to obtain a value for the ratio of expressed GSK-3␤. As shown in the bar graph, the total GSK-3␤ decrease after using ␤-actin standardized protein loading, (C) GSK-3␤ expression in N2a/A␤PPswe treated with different drugs: Cells were plated in 6 well plate for overnight and then drugs were added into each designated wells in duplicate. Cells were lysed after 36 hours incubation. Proteins were loaded onto SDS-page gel and then blotted with each antibody after transfer onto PVDF membrane. Groups are: CTRL, Control; M1T2, 10 −5 M Melatonin + 2.5 nM THC; M2T2, 10 −6 M Melatonin + 2.5 nM THC; T1, THC 25 nM; T2, THC 2.5 nM; T3, THC 0.25 nM, (D) Expression of pGSK-3␤ following melatonin and THC treatment in N2a/A␤PPswe cells. *The same batch protein samples were used in this test as in Fig. 7C . Bands were quantified. One-way ANOVA was applied to the data. p < 0.05 when compared with control group. **p < 0.01 when compared with control group. 
